Recombinant tissue plasminogen activator (rt-PA) in acute ischemic stroke
Canadian Coordinating Office for Health Technology Assessment
Record ID 32004000859
English, French
Authors' objectives:
To summarize the available information on the use of recombinant tissue plasminogen activator (re-PA) in acute ischemic stroke.
Authors' recommendations:
Overall, it seems that rt-PA, when administered in a tertiary care neurological centre up to three hours after the onset of stroke symptoms, can decrease the disability of acute stroke survivors. No significant mortality benefit, however, has been demonstrated. Treatment given outside specialized centres may result in more harm from intercranial hemorrhage than benefit, especially if treatment guidelines are not followed. More research is needed to define optimal stroke population and time window for treatment initiation.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
2004
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Recombinant Proteins
- Stroke
- Tissue Plasminogen Activator
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.